ECDC is monitoring reports from three countries (France, the United Kingdom and the United States) of cases of invasive meningococcal disease (IMD) associated with travel to the Kingdom of Saudi Arabia (KSA).
European Immunization Week (EIW) is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
In connection with the European Immunization Week, ECDC releases data indicating an increase in cases of vaccine-preventable diseases such as measles and pertussis, after decreased levels during the COVID-19 pandemic.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.
Hepatitis A cases in 2021 were at their lowest levels since EU-level hepatitis A surveillance began in 2007, while five other food and waterborne diseases are rising towards pre-pandemic levels. The information is revealed in the Annual Epidemiological Report 2021, of which six chapters are published today by ECDC.
Nearly one in three foodborne outbreaks in the EU in 2018 were caused by Salmonella. This is one of the main findings of the annual report on trends and sources of zoonoses published today by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC).
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.